BC
RARE icon

Birchview Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Birchview Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,000
Closed -$1.3M – 81
2026
Q1 		$1.3M Hold
62,000
– – 0.74% 36
2025
Q4 		$1.43M Buy
62,000
+40,000
+182% +$1.32M 0.83% 32
2025
Q3 		$662K Buy
22,000
+4,000
+22% +$120K 0.5% 45
2025
Q2 		$654K Buy
18,000
+2,000
+13% +$72.1K 0.65% 35
2025
Q1 		$579K Hold
16,000
– – 0.5% 30
2024
Q4 		$673K Buy
+16,000
New +$794K 0.55% 26

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Birchview Capital's RARE Position: Q2 2026 in Review

Birchview Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 62,000 shares — an estimated $1.3M sold.

Birchview Capital first reported a position in RARE in Q4 2024 and held it in 6 quarters. The position peaked at $1.43M in Q4 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Birchview Capital reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Birchview Capital sold 62,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.3M.
  • Birchview Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • Birchview Capital's Ultragenyx Pharmaceutical position peaked at $1.43M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.